Orthogonal reaction controlled phase-separated aggregate, method for preparing same, and use
Through the phase separation agglutination technology regulated by orthogonal reaction, a nucleic acid protein combination is formed using the click-release strategy, which solves the problem of drug retention in tumor cells and significantly improves the effect of cancer treatment and the survival time of mice.
Patent Information
- Application Number
- PCT/CN2023/095383
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-19
- Publication Date
- 2024-11-28
AI Technical Summary
During cancer treatment, drugs are easily actively pumped out by the proteins of drug-resistant cells, resulting in treatment failure and tumor recurrence. The prior art is difficult to effectively improve the retention and therapeutic effect of drugs in tumor cells.
The phase separation agglutinous group regulated by orthogonal reaction is used to seal in vitro and recover in cells through a click-release strategy to form a controllable long-term drug agglutinous group. The phase separation is used for modified proteins and nucleic acids to form a nucleic acid protein combination , embedded drugs to improve drug concentration and retention.
The anti-tumor effect of the drug was significantly improved, the survival time of the tumor-affected mice was prolonged, and the drug retention rate and efficacy were improved in drug-resistant cells, significantly inhibiting tumor growth.
Smart Images

Figure 000013 
Figure 000014 
Figure 000015
Abstract
Description
A phase separation aggregate regulated by orthogonal reaction and a method for preparing the same and its application Technical Field
[0001] The present invention relates to the field of drug delivery, and in particular to a phase-separated aggregate regulated by an orthogonal reaction, and a method for preparing the same and an application thereof. Background Art
[0002] During the treatment of cancer with chemotherapy drugs, multidrug resistance (MDR) gradually develops. Drugs that enter tumor cells are actively pumped out by proteins (ABC transporters) overexpressed by resistant cells, leading to treatment failure and tumor recurrence and metastasis. By developing new strategies to enhance drug retention in resistant cells, we can maintain effective therapeutic doses and achieve optimal therapeutic effects.
[0003] Liquid-liquid phase separation (LLPS) forms membraneless organelles such as stress granules, nucleoli or Cajal bodies through multiple interactions between biomacromolecules such as proteins, DNA and RNA, which has attracted widespread attention in recent years. At present, research on liquid-liquid phase separation tends to explore the mechanism, focusing on revealing the intrinsic driving force of liquid-liquid phase separation, the specific process of intracellular compartmentalization and its association with a series of physiological activities, such as intracellular communication, transcriptional regulation, stress response and disease occurrence, but there are relatively few explorations on the practical application of liquid-liquid phase separation systems. In the crowded environment inside the cell, which is full of biomacromolecules such as proteins and nucleic acids, these biomacromolecules tend to form concentrated aggregates under volume exclusion, making the molecular concentration therein hundreds of times higher than that in the cytoplasm, thereby changing the existence state of the molecules and the balance of biochemical reactions. Inspired by this, the applicant envisions that phase separation aggregates can be used to concentrate cancer treatment preparations, thereby increasing the effective drug dose and avoiding the clearance of drugs by drug-resistant tumors, thereby improving the effect of cancer treatment. However, due to the dynamic nature of aggregates and their susceptibility to environmental parameters, the controllable preparation of aggregates is a great challenge.
[0004] Bioorthogonal reactions are reactions that can be carried out in living cells or tissues without interfering with the organism's own biochemical reactions. These reactions offer excellent biochemical control and biosafety, providing a solution to the instability of these biomolecular aggregates. Therefore, we proposed a synthetic method for in situ assembly of liquid-liquid phase-separated aggregates. Using a bioorthogonal click-release strategy, we achieved in vitro sequestration and intracellular recovery of the phase-separated system, thereby forming controllable aggregates with long-lasting drug retention, enhancing the efficacy of cancer treatment.
[0005] Summary of the Invention
[0006] The purpose of the present invention is to provide a phase separation aggregate regulated by an orthogonal reaction and a method for preparing the same and an application thereof, so as to solve the problem of drug resistance in the treatment of cancer or drug-resistant bacterial infection.
[0007] In order to solve the above technical problems, the first aspect of the present invention provides a nucleic acid-protein combination that can form a phase-separated aggregate, which comprises: a modified protein and a modified nucleic acid, wherein the nucleic acid includes DNA and RNA, and the modified protein and the modified nucleic acid can undergo a click-release reaction, causing the protein and the nucleic acid to phase separate to form the phase-separated aggregate.
[0008] In some embodiments, the click-release reaction is performed in vitro in a cell-free solution or intracellularly.
[0009] In some embodiments, the modified protein is a (2E)TCO-modified protein, ie, protein-TCO, and the modified nucleic acid is a tetrazine-modified nucleic acid, ie, nucleic acid-Tz.
[0010] In some embodiments, when the click-release reaction is performed in a cell-free solution in vitro, the concentration of the protein is greater than 1 mg / mL, preferably less than 5 mg / mL, and the concentration of the DNA is greater than 20 μM, preferably less than 100 uM.
[0011] In some embodiments, the concentration of the protein is greater than 2 mg / mL and less than 5 mg / mL, and the concentration of the DNA is greater than 30 μM and less than 100 uM.
[0012] In some embodiments, when the click-release reaction is performed intracellularly, the concentration of the protein is greater than 50 μg / mL, preferably less than 200 μg / mL, and the concentration of the DNA is greater than 1 μM, preferably less than 10 μM.
[0013] In some embodiments, the concentration of the protein is greater than 100 μg / mL and less than 200 μg / mL, and the concentration of the DNA is greater than 5 μM and less than 10 μM.
[0014] In some embodiments, the protein is selected from proteins with phase separation ability, preferably amino-rich proteins; the nucleic acid is selected from nucleic acids rich in repetitive base sequences and capable of stable existence, such as double-stranded DNA or double-stranded RNA containing repeated CG base pairs.
[0015] In some embodiments, the amino-rich protein comprises a histone or a prion-like protein, such as FUS (fused us sarcoma).
[0016] In some embodiments, the protein has a molecular weight range of 10-20 kDa.
[0017] In some embodiments, the nucleic acid is 25 to 30 bp in length.
[0018] In some embodiments, the histone is selected from one or more of histones H1, H2A, H2B, H3 and H4; the two single-stranded nucleotide sequences of the DNA are shown as SEQ ID NO: 1 (sequence-1) and SEQ ID NO: 2 (sequence-2), respectively.
[0019] The second aspect of the present invention provides a drug combination comprising the nucleic acid protein combination described in the first aspect of the present invention and a drug.
[0020] In some embodiments, the drug intercalates into a CG base pair of a nucleic acid.
[0021] In some embodiments, the drug is selected from one or more of doxorubicin, mitoxantrone, cisplatin, and tetracycline.
[0022] The third aspect of the present invention provides a kit, which comprises the nucleic acid-protein combination described in the first aspect of the present invention.
[0023] In some embodiments, the kit further comprises one or more of (2E)TCO, (4E)TCO, azide, and tetrazine.
[0024] In some embodiments, the kit further comprises one or more drugs selected from the group consisting of doxorubicin, mitoxantrone, cisplatin, and tetracycline.
[0025] A fourth aspect of the present invention provides a method for preparing an agglomerate, the method comprising the following steps:
[0026] The protein-TCO and nucleic acid-Tz in the nucleic acid-protein combination described in the first aspect of the present invention are reacted to produce the aggregate.
[0027] In some embodiments, the reaction is performed in vitro in a cell-free solution or intracellularly.
[0028] In some embodiments, the method further comprises the following steps:
[0029] (1) Reacting the protein with (2E)TCO-PEG4-NHS to prepare protein-TCO;
[0030] (2) Reacting azide-modified double-stranded DNA or double-stranded RNA with DBCO-Tz to prepare double-stranded DNA-Tz or double-stranded RNA-Tz.
[0031] A fifth aspect of the present invention provides a method for preparing drug-containing aggregates, the method comprising the following steps:
[0032] (1) loading the drug into the nucleic acid-Tz, such as double-stranded DNA-Tz or double-stranded RNA-Tz, in the nucleic acid-protein combination described in the first aspect of the present invention;
[0033] (2) Reacting the protein-TCO with the drug-loaded double-stranded DNA-Tz or double-stranded RNA-Tz to produce the drug-containing aggregates.
[0034] In some embodiments, the reaction is performed in vitro in a cell-free solution or intracellularly.
[0035] In some embodiments, the method comprises the following steps:
[0036] (1) Reacting the protein with (2E)TCO-PEG4-NHS to prepare protein-TCO;
[0037] (2) reacting the azide-modified double-stranded DNA or double-stranded RNA with DBCO-Tz to prepare double-stranded DNA-Tz or double-stranded RNA-Tz;
[0038] (3) loading the drug into double-stranded DNA-Tz or double-stranded RNA-Tz;
[0039] (4) The protein-TCO is reacted with double-stranded DNA-Tz or double-stranded RNA-Tz loaded with drugs to generate drug-containing aggregates.
[0040] In some embodiments, the reaction is performed in vitro in a cell-free solution or intracellularly.
[0041] The sixth aspect of the present invention provides the use of the nucleic acid-protein combination described in the first aspect of the present invention or the drug combination described in the second aspect of the present invention in the preparation of a drug or kit for treating tumors or drug-resistant bacterial infections.
[0042] On the basis of conforming to the common sense in this field, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0043] The reagents and raw materials used in the present invention are commercially available.
[0044] The positive progress effect of the present invention is:
[0045] The present invention innovatively proposes a nucleic acid-protein combination and a method for preparing phase-separated aggregates using this combination, achieving controllable aggregate preparation and long-term retention of active ingredients. The nucleic acid-protein combination comprises two separate components outside the cell and can form phase-separated aggregates inside the cell through click chemistry reactions. This can significantly enhance the anti-tumor efficacy of drugs and significantly prolong the survival of tumor-bearing mice. Drug retention strategies based on these aggregates can significantly improve drug efficacy. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1A shows the morphology of droplets formed by histones and FITC-labeled DNA under a confocal microscope. The scale bar is 20 μm.
[0047] FIG1B is a photograph of histone, DNA, and aggregate solutions.
[0048] Figure 1C shows the turbidity assay for histones, DNA, and aggregates.
[0049] Figure 1D shows the fluorescence recovery of the droplet after photobleaching.
[0050] FIG2A shows the double-stranded DNA sequence structure bound to the drug doxorubicin.
[0051] Figure 2B shows the adsorption of drugs by the constructed aggregates.
[0052] FIG2C shows the time course of drug adsorption into the aggregates.
[0053] Figure 3A shows the type of click-release reaction.
[0054] FIG3B is a schematic diagram of a click-release reaction based on a (2E)TCO group and a click-ligation reaction based on a (4E)TCO group.
[0055] FIG3C shows the attenuation of the absorbance of the Tz group at 530 nm after reaction with the TCO group.
[0056] FIG3D shows the release curve of the loaded molecule Rhodamine B (RB) after the (2E)TCO and (4E)TCO groups reacted with the Tz group, respectively.
[0057] FIG4A is a mass spectrometric characterization of the molecular weight change of histones before and after the reaction with (2E)TCO-PEG4-NHS.
[0058] FIG4B is a mass spectrometric representation of the molecular weight change of azide-modified DNA before and after the reaction with DBCO-Tz.
[0059] FIG5 shows the process of aggregate formation triggered by liquid-liquid phase separation of bioorthogonal reactions in an embodiment of the present invention. The upper part of the figure shows the process of aggregate formation triggered by click-release reaction, and the lower part shows the control group of click-ligation reaction.
[0060] Figure 6 shows the formation of aggregates in cells according to an embodiment of the present invention. The left figure shows a confocal image of aggregate formation by a 2E-conjugate click-release reaction in cells. The right figure shows a control group in which a 4E-conjugate click-ligation reaction in cells failed to trigger aggregate formation. Scale bar: 20 μm.
[0061] FIG7A shows the effect of 2E-conjugate on the activity of 4T1 cancer cells.
[0062] Figure 7B shows the toxicity test of 2E-conjugate on drug-resistant cancer cells 4T1 / ADR.
[0063] FIG8A is a verification of the killing effect of the drug alone and the drug-loaded aggregates formed in the cells on 4T1 cells.
[0064] FIG8B is a verification of the killing effect of the drug alone and the drug-loaded aggregates formed in the cells on 4T1 / ADR cells.
[0065] FIG9A shows the retention rates of drug alone, aggregates / drug, and non-aggregates / drug in 4T1 cells after 12 hours of treatment.
[0066] FIG9B shows the retention rates of drug alone, aggregates / drug, and non-aggregates / drug in 4T1 / ADR cells after 12 hours of treatment.
[0067] FIG9C is a time-dependent drug retention assay of different groups in 4T1 / ADR cells.
[0068] FIG10A shows the time-dependent changes in the intracellular contents of doxorubicin, aggregates / drugs, and non-aggregates / drugs.
[0069] FIG10B is a statistical analysis of FIG10A , showing the average drug fluorescence intensity in cells at different time points.
[0070] Figure 11A shows the co-localization of drug and aggregate fluorescence after the Cy5-labeled aggregates + drug group and the Cy5-labeled non-aggregates + drug group acted on cells. Scale bar: 20 μm.
[0071] FIG11B is a statistical analysis of FIG11A , showing the fluorescence co-localization coefficients of drugs and aggregates in different groups at different time points.
[0072] FIG11C is a statistical analysis of FIG11A , showing the average drug adsorption intensity of different groups at different time points.
[0073] FIG12A is a graph showing bioluminescent imaging of tumors in the 4T1 mouse tumor model at different days after treatment in each group of mice.
[0074] FIG12B shows the tumor growth of mice in each group after treatment in the 4T1 mouse tumor model.
[0075] FIG13A is the average tumor growth curve of each group of mice after treatment in the 4T1 mouse tumor model.
[0076] FIG13B shows the survival curves of mice in each group after treatment in the 4T1 mouse tumor model.
[0077] FIG14A is the average tumor growth curve of each group of mice after treatment in the 4T1 / ADR mouse tumor model.
[0078] FIG14B shows the tumor growth of mice in each group after treatment in the 4T1 / ADR mouse tumor model.
[0079] FIG14C is a photo of the tumors in each group of mice after 12 days of treatment in the 4T1 / ADR mouse tumor model.
[0080] FIG15A shows drug retention after intratumoral injection of drugs and formulations.
[0081] FIG15B shows the adsorption of drugs injected via the tail vein by the drug depot formed in the tumor. DETAILED DESCRIPTION
[0082] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.
[0083] Example 1: Preparation of Aggregates and Construction of Drug Depots
[0084] 4 μL of histone (5 mg / mL, Sangon Biotech (Shanghai) Co., Ltd.), 4 μL of DNA (100 μM, Sangon Biotech (Shanghai) Co., Ltd.), and 2 μL of PEG 3350 (250 mg / mL, Shanghai MacLean Biochemical Technology Co., Ltd.) were thoroughly mixed, transferred to a glass slide, covered with a coverslip, and observed under a microscope. The absorbance at 600 nm was measured using a microplate reader to reflect the turbidity of the solution. The solution was observed under a confocal laser scanning microscope. Selected areas were laser-bleached, and the recovery of fluorescence intensity in the bleached areas was monitored. The results showed that liquid-liquid phase separation occurred between the histones and DNA, forming droplets (Figure 1A), accompanied by an increase in solution turbidity (Figures 1B and 1C). The droplets exhibited dynamic properties, and after laser bleaching of a portion of the area, the fluorescence intensity of the DNA recovered within 50 s (Figure 1D).
[0085] Equal amounts of Seq-1 and Seq-2 were dissolved in PBS buffer (pH 7.4) and incubated at 40°C for 15 minutes to form DNA duplexes. 50 μL of PBS, histone (2 mg / mL), DNA duplex (50 μM), and aggregates (C histone = 2 mg / mL, C DNA duplex = 50 μM) were then mixed with 50 μL of doxorubicin (Dox) (5 μM, Shanghai MacLean Biochemical Technology Co., Ltd.), and the fluorescence intensity of Dox was monitored over 30 minutes. The results showed that the DNA duplex sequence was designed to allow the anticancer drug Dox to intercalate into the CG base pairs of the DNA duplex (Figure 2A). Successful loading was confirmed by quenching of the drug's fluorescence intensity (Figure 2B). After forming phase-separated aggregates with histones, the DNA also adsorbed the drug, reaching adsorption equilibrium within 30 minutes (Figure 2C).
[0086] Example 2: Bioorthogonal reaction
[0087] 1. Click reaction:
[0088] The applicants conducted experimental exploration of different types of click-release reactions (Figure 3A) and found that only one type of reaction is suitable for the formation of intracellular histone and nucleic acid aggregates, namely the click-release reaction based on the Tz-TCO reaction pair. Other click-release orthogonal reactions based on Tz-vinyl ethers and Tz-vinyl boronic acid cannot trigger the formation of intracellular phase separation aggregates. When performing this type of reaction, (2E)TCO groups and (4E)TCO groups were selected to modify histones respectively. It was found that aggregates could be formed only when the (2E)TCO group was modified. The specific operation is as follows:
[0089] 5 μL of gradient concentrations of (2E)TCO-PEG4-NHS or (4E)TCO-PEG4-NHS (0.02, 0.05, 0.1, 0.2, 0.5, 1 mM) (Xi'an Ruixi Biotechnology Co., Ltd.) was reacted with 5 μL of Methyltetrazine-DBCO (1 mM, Click Chemistry Tools, USA) at room temperature for 5 minutes, and the absorbance of the solution was measured. The attenuation of the Tz group at 530 nm was used to reflect the click reaction between TCO and Tz groups.
[0090] 2. Release reaction:
[0091] First, RB-PEG-NH2 was reacted with (2E)TCO-PEG4-NHS Ester or (4E)TCO-PEG4-NHS Ester to obtain (2E)TCO-RB or (4E)TCO-RB. Then, 75 μL of (2E)TCO-RB or (4E)TCO-RB (120 μg / mL) was mixed with 75 μL of Duplex-Tz (100 μM) and placed in a microdialysis tube (Slide-A-Lyzer TM MINI Dialysis Device, 10K MWCO), the outer tube dialysate was 13.5mL PBS. At a specific time, 100μL of the outer tube dialysate was taken out to detect the release amount of RB-PEG-NH2 (Shanghai Aladdin Biochemical Technology Co., Ltd.) (measuring the emission fluorescence intensity of the dialysate at 590nm under excitation at a wavelength of 530nm). The results showed that the click-release reaction based on the (2E)TCO group and the Tz group can release the amino-containing load, and the click-ligation reaction based on the (4E)TCO group and the Tz group cannot release the load (Figure 3B), so it was used as the control group for subsequent experiments. Both click-release and click-ligation reactions can change the structure of the Tz group, and the absorbance value at 530nm decreases (Figure 3C). Compared with the click-ligation reaction, the click-release reaction can release more than 80% of the load within about 4 hours (Figure 3D).
[0092] 3. Histone modification:
[0093] 2.5 mg of histone was dissolved in 10 mL of NaHCO3 aqueous solution (0.1 M, pH = 8.4), and 50 μL of (2E)TCO-PEG4-NHS or (4E)TCO-PEG4-NHS (10 mg / mL in DMSO) was added. After reacting at room temperature for 4 h, the product was dialyzed against ultrapure water for 1 day and freeze-dried.
[0094] 4. DNA modification:
[0095] 1 mL of DNA-N3 (20 μM in PBS buffer) was mixed with 100 μL of DBCO-Tz (1 mM in PBS buffer) and allowed to react on an oscillator at 600 rpm for 72 hours at room temperature. The mixture was dialyzed and lyophilized. The results showed that the reaction of histones with (2E)TCO-PEG4-NHS and the reaction of azide-modified DNA with DBCO-Tz resulted in the attachment of TCO groups to histones and Tz groups to DNA, respectively, designated as Histone-TCO and DNA-Tz. Mass spectrometry analysis of the changes in molecular weight before and after modification confirmed the successful attachment of histones to TCO groups and DNA to Tz groups (Figures 4A and 4B).
[0096] 4 μL (2E)Histone-TCO (5 mg / mL) or (4E)Histone-TCO (5 mg / mL), 4 μL DNA-FITC (100 μM), and 2 μL PEG 3350 (250 mg / mL) were thoroughly mixed, transferred to a glass slide, covered with a coverslip, and observed under a confocal microscope. The results showed that when DNA-Tz reacted with (2E)Histone-TCO or (4E)Histone-TCO, (2E)Histone-TCO and DNA-Tz underwent a click-release reaction, releasing amino-containing histones that separated from DNA and formed a large number of aggregates. However, when (4E)Histone-TCO and DNA-Tz underwent a click-ligation reaction, the amino-containing histones could not be released, and the amount of aggregates formed was limited (Figure 5). This shows that the liquid-liquid phase separation controlled by the bioorthogonal reaction proposed in the present invention is feasible.
[0097] Example 3: Formation of intracellular aggregates, biocompatibility testing, and anticancer effects of aggregates at the cellular level
[0098] 4T1 / ADR cells were incubated with equal concentrations of the protein-nucleic acid conjugates 2E-conjugate or 4E-conjugate, with histone and DNA duplex concentrations at 50 μg / mL and 1 μM, respectively. Aggregate formation was observed under a confocal microscope at different time points. The results showed that the formation of phase-separated aggregates triggered by the click-release reaction was also observed in the cells (Figure 6).
[0099] 4T1 and 4T1 / ADR cells were cultured at 5×10 3 Cells were seeded at a density of 100 μL / well in a 96-well plate. After 24 hours of adherence, gradient concentrations of 2E-conjugate were added to the culture medium for 48 hours. Subsequently, the cells were incubated with MTT solution (0.5 mg / mL) for 4 hours. 100 μL of DMSO was then used to dissolve the resulting blue-purple formazan crystals. Cell viability was measured by measuring absorbance at 490 nm using a microplate reader. Calculation formula: Cell viability = OD490 nm (Treatment group) / OD490 nm (Control group) The results showed that the aggregates formed within the cells had no significant effect on the activity of 4T1 cancer cells and drug-resistant 4T1 cells (4T1 / ADR) (Figure 7A, Figure 7B), indicating that the preparation has good biocompatibility.
[0100] The drug-loaded 2E-conjugate (i.e., 2E-conjugate / Dox) was used as a control group (i.e., the doxorubicin group, the same below) with gradient concentrations of Dox alone, and as an experimental group (i.e., the aggregate / drug group) with gradient concentrations of 2E-conjugate / Dox. All other procedures remained unchanged, and the cell viability of 4T1 and 4T1 / ADR cells was observed. The results showed that the intracellular aggregates significantly enhanced the killing effect of the drug on 4T1 cells and 4T1 / ADR cells, and the killing ability increased with increasing doxorubicin concentration (Figures 8A and 8B).
[0101] Example 4: Intracellular drug retention
[0102] Drug-resistant cells were seeded into 96-well plates and incubated for 24 hours after attachment with Dox, 2E-conjugate / Dox (i.e., aggregate / drug group, the same below), and 4E-conjugate / Dox (i.e., non-aggregate / drug group, the same below) for 4 hours (drug concentration was 10 μM). Subsequently, the culture medium was removed, washed twice with PBS, and incubated with fresh medium without drug. At certain time intervals, the medium was removed and replaced with fresh medium, and the intracellular drug fluorescence intensity was measured. The results showed that, by quantifying the intracellular drug fluorescence intensity, it was confirmed that the aggregates increased the drug retention rate in both 4T1 cells and 4T1 / ADR cells (Figures 9A and 9B), and drug retention could still be detected after 24 hours of action (Figure 9C).
[0103] Cells were seeded on confocal dishes and adhered for 24 hours before being incubated with Dox alone, 2E-conjugate / Dox, and 4E-conjugate / Dox for different periods of time. In these preparations, the drug concentration was 10 μM, and the histone and DNA double-strand concentrations were 200 μg / mL and 10 μM, respectively. The culture medium was then removed, the cells were washed twice with PBS, and the nuclei were stained with Hoechst 33342. After the cells were fixed, the intracellular drug fluorescence intensity was observed. The results showed that through confocal qualitative experiments, the fluorescence intensity increased over time (Figure 10A), confirming that the red fluorescent drug can be retained in the cells for a long time by the aggregates (Figure 10B).
[0104] Example 5: Adsorption of drugs by aggregates
[0105] 4T1 / ADR cells were pretreated with drug-free 2E-conjugate-Cy5 (DNA was modified with Cy5 during DNA-Tz preparation) and 4E-conjugate-Cy5 for 4 hours to form intracellular aggregates. The medium was then removed and replaced with drug-containing medium (drug concentration: 10 μM) for various incubation times. Fluorescence colocalization of drug and Cy5-labeled DNA was observed under a confocal microscope. The fluorescence colocalization coefficient and drug adsorption were analyzed using Image J software. The results showed that the red fluorescent drug was adsorbed to the Cy5-labeled aggregates compared to the non-aggregate group (Figure 11A). Furthermore, the fluorescence colocalization coefficients of the aggregates + drug group were higher than those of the non-aggregate + drug group at different time points (Figure 11B). The average drug adsorption intensity was also higher in the aggregates + drug group than in the aggregates + drug group (Figure 11C), confirming the strong drug adsorption capacity of the aggregates.
[0106] Example 6: In vivo efficacy experiment
[0107] 4T1 or 4T1 / ADR cells were inoculated into the back of Balb / c nude mice, and the tumors were grown to about 100 mm. 3 The mice were randomly divided into four groups, with 6 mice in each group, and were given drugs respectively: Group G1: PBS; Group G2: 2E-conjugate; Group G3: Dox; Group G4: 2E-conjugate / Dox. For 4T1 and 4T1 / ADR tumor-bearing mice, the drug concentrations were 0.25 mg / kg and 2.5 mg / kg, respectively. The drugs were given every three days, and the tumor volume and mouse weight were measured every two days. When the tumor volume of the mouse exceeded 1500 mm 3 , and the mice were euthanized. The results showed that in the 4T1 mouse tumor model, tumor luminescence imaging showed that the tumor in the aggregate / drug group was the smallest (Figure 12A), and the tumor size in the aggregate / drug group was the smallest (Figure 12B). As the number of treatment days increased, the size of the aggregate / drug group tumor increased slowly (Figure 13A), and the survival rate increased significantly (Figure 13B). In the 4T1 and 4T1 / ADR mouse tumor models, the size of the aggregate / drug group tumor increased slowly after drug administration (Figure 14A), the tumor size in the aggregate / drug group was the smallest (Figure 14B), and the mouse tumor volume was significantly suppressed (Figure 14C). In vivo efficacy experiments confirmed that aggregates can significantly enhance the anti-tumor effect of drugs, significantly prolonging the survival time of mice. The drug retention strategy based on aggregates can significantly improve the efficacy of drugs.
[0108] Example 7: Drug Accumulation in Tumor Tissue
[0109] 1. Drug retention:
[0110] Tumor-bearing mice were intratumorally injected with Dox, 2E-conjugate / Dox, and 4E-conjugate / Dox. 24 hours later, the mice were euthanized, and the tumor tissues were removed. Frozen sections were made, and the cells were stained with DAPI. The retention of the drug in the tumor tissue was observed under a confocal microscope.
[0111] 2. Drug adsorption:
[0112] Tumor-bearing mice were intratumorally injected with PBS, 2E-conjugate, and 4E-conjugate, along with doxorubicin via the tail vein. Twenty-four hours later, the mice were euthanized, and tumor tissue was removed and frozen sections prepared. Cells were stained with DAPI, and drug adsorption within the tumor tissue was observed under a confocal microscope. The results demonstrated that the bioorthogonal click-release reaction not only serves as a drug delivery system, utilizing its larger size retardation to enhance intracellular drug retention (Figure 15A), but also allows for adsorption of tail vein-injected drugs through a drug reservoir formed within the tumor, thereby achieving drug elevation within the tumor tissue (Figure 15B) and enhancing anti-tumor efficacy.
[0113] Although the above describes specific embodiments of the present invention, it should be understood by those skilled in the art that these are merely illustrative and that various changes or modifications may be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.
Claims
1. A nucleic acid-protein combination capable of forming a phase-separated aggregate, characterized in that: The invention comprises: modified protein and modified nucleic acid, wherein the nucleic acid comprises DNA and RNA, and the modified protein and the modified nucleic acid can undergo click-release reaction, so that the protein and the nucleic acid are phase-separated to form the phase-separated aggregate.
2. The nucleic acid-protein combination according to claim 1, characterized in that: The click-release reaction is carried out in vitro in a cell-free solution or intracellularly; and / or, the modified protein is a (2E)TCO-modified protein, i.e., protein-TCO, and the modified nucleic acid is a tetrazine-modified nucleic acid, i.e., nucleic acid-Tz; Preferably, when the click-release reaction is carried out in an in vitro cell-free solution, the concentration of the protein is greater than 1 mg / mL, preferably less than 5 mg / mL, and the concentration of the DNA is greater than 20 μM, preferably less than 100 μM; more preferably, the concentration of the protein is greater than 2 mg / mL and less than 5 mg / mL, and the concentration of the DNA is greater than 30 μM and less than 100 μM; Or, when the click-release reaction is carried out intracellularly, the concentration of the protein is greater than 50 μg / mL, preferably less than 200 μg / mL, and the concentration of the DNA is greater than 1 μM, preferably less than 10 μM; more preferably, the concentration of the protein is greater than 100 μg / mL and less than 200 μg / mL, and the concentration of the DNA is greater than 5 μM and less than 10 μM.
3. The nucleic acid-protein combination according to claim 1 or 2, characterized in that: The protein is selected from proteins with phase separation ability, preferably amino-rich proteins; the nucleic acid is selected from nucleic acids rich in repetitive base sequences and capable of stable existence, such as double-stranded DNA or double-stranded RNA containing repeated CG base pairs; Preferably, the amino-rich protein comprises a histone or a prion-like protein, such as FUS; and / or, the molecular weight of the protein is in the range of 10-20 kDa; and / or, the length of the nucleic acid is 25 to 30 bp; More preferably, the histone is selected from one or more of histones H1, H2A, H2B, H3 and H4; and the two single-stranded nucleotide sequences of the DNA are shown as SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
4. A drug combination, characterized in that It comprises the nucleic acid protein combination as claimed in any one of claims 1 to 3 and a drug; Preferably, the drug is embedded in the CG base pair of the nucleic acid; and / or, the drug is selected from one or more of doxorubicin, mitoxantrone, cisplatin and tetracycline.
5. A kit, characterized in that: The kit comprises the nucleic acid-protein combination according to any one of claims 1 to 3; Preferably, the invention further comprises one or more of (2E)TCO, (4E)TCO, azide and tetrazine; and / or further comprises one or more drugs selected from doxorubicin, mitoxantrone, cisplatin and tetracycline.
6. A method for preparing an agglomerate, characterized in that: The method comprises the following steps: The protein-TCO and nucleic acid-Tz in the nucleic acid-protein combination according to any one of claims 1 to 3 are reacted to produce generating the agglomerate; Preferably, the reaction is performed in vitro in a cell-free solution or intracellularly.
7. The method according to claim 6, characterized in that The method further comprises the following steps: (1) reacting the protein with (2E)TCO-PEG4-NHS to prepare protein-TCO; (2) reacting the azide-modified double-stranded DNA or double-stranded RNA with DBCO-Tz to prepare double-stranded DNA-Tz or double-stranded RNA-Tz.
8. A method for preparing a drug-containing aggregate, characterized in that: The method comprises the following steps: (1) loading the drug into the nucleic acid-Tz such as double-stranded DNA-Tz or double-stranded RNA-Tz in the nucleic acid-protein combination as described in any one of claims 1 to 3; (2) reacting the protein-TCO with double-stranded DNA-Tz or double-stranded RNA-Tz loaded with the drug to produce the drug-containing aggregate; preferably, the reaction is carried out in vitro in a cell-free solution or intracellularly.
9. The method according to claim 8, characterized in that The method comprises the following steps: (1) reacting the protein with (2E)TCO-PEG4-NHS to prepare protein-TCO; (2) reacting the azide-modified double-stranded DNA or double-stranded RNA with DBCO-Tz to prepare double-stranded DNA-Tz or double-stranded RNA-Tz; (3) loading the drug into double-stranded DNA-Tz or double-stranded RNA-Tz; (4) reacting the protein-TCO with double-stranded DNA-Tz or double-stranded RNA-Tz loaded with drugs to generate drug-containing aggregates; preferably, the reaction is carried out in vitro in a cell-free solution or intracellularly.
10. Use of the nucleic acid-protein combination according to any one of claims 1 to 3 or the drug combination according to claim 4 in the preparation of a drug or kit for treating tumors or drug-resistant bacterial infections.
Citation Information
Patent Citations
Fixed-point coupling method and conjugate of clustered regularly interspaced short palindromic repeats (CRISPR) family protein and nucleic acid and application of conjugate
CN112779240A
Rapid and efficient click release compounds
CN115135628A
No title available
GB1440626A
CD38 Ligand-Drug Conjugates For Targeted Cancer Therapy
US20180078649A1
System and method for delivery of DNA-binding chemotherapy drugs using nanoparticles
WO2012061402A2
